Across the pharmaceutical industry, forging collaborations are a key tool to bringing new medications through the clinic and to market. This week, multiple companies have partnered in attempts to bring forth new therapies. BioSpace took a look at some of these announcements.

Eli Lilly said on May 27 the company received a subpoena from the U.S. Department of Justice related to the New Jersey plant that makes the Covid-19 treatment, bamlanivimab.

Alzheimer’s disease is the holy grail of pharmaceutical research, and a team of physicians published results showing that they may have found the key to actually improving cognition in patients with early-stage dementia.

Newly announced topline results from Eli Lilly’s SURPASS-4 trial program show the company’s investigational diabetes agent, tirzepatide, significantly reduced blood glucose levels and body weight better than insulin glargine in adult patients with type 2 diabetes. 

Eli Lilly will harness the power of MiNA Therapeutics’ proprietary small activating RNA (saRNA) technology platform to develop five novel drug candidates against diseases across the company’s core areas of focus.

Regeneron Pharmaceuticals Inc. reported a better-than-expected quarterly profit on May 6 and expects demand for the company’s Covid-19 antibody therapy to hold up even as vaccination efforts across the United States intensify.

The European Medicines Agency will conduct an accelerated review of Eli Lilly and Co.’s rheumatoid arthritis drug Olumiant for hospitalized Covid-19 patients getting oxygen, the EU agency said on April 29, as the search for treatment options continues.

Eli Lilly released the company’s first-quarter 2021 financial report and is abandoning plans to submit mirikizumab to health regulators for psoriasis.

The tenth annual Pharmaceutical Innovation Index, released April 21, sees Eli Lilly top the industry for the first time. The Pharmaceutical Invention Index, a ranking of the industry’s best pipelines, rated Bristol Myers Squibb as No. 1.

Eli Lilly requested cancellation of the U.S. authorization granted to the company’s Covid-19 antibody bamlanivimab, which will now be used in combination with another to achieve greater efficacy against emerging virus variants.